Indication

As monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy

Medicine details

Medicine name:
epcoritamab (Tepkinly)
SMC ID:
SMC2632
Pharmaceutical company
AbbVie Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
10 June 2024
SMC meeting date:
07 May 2024
Patient group submission deadline:
TBC